Osaic Holdings
ABCL icon

Osaic Holdings’s AbCellera Biologics ABCL Stock Holding History

Osaic Holdings’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Buy
348,978
+1,657
+0.5% +$5.96K ﹤0.01% 2516
2025
Q4 		$1.19M Buy
347,321
+4,246
+1% +$19K ﹤0.01% 2528
2025
Q3 		$1.44M Buy
343,075
+75,074
+28% +$331K ﹤0.01% 2467
2025
Q2 		$919K Buy
268,001
+52,227
+24% +$130K ﹤0.01% 2580
2025
Q1 		$481K Buy
215,774
+83,760
+63% +$240K ﹤0.01% 2912
2024
Q4 		$387K Buy
132,014
+27,760
+27% +$77.3K ﹤0.01% 3025
2024
Q3 		$271K Sell
104,254
-2,223
-2% -$6.16K ﹤0.01% 3400
2024
Q2 		$315K Buy
106,477
+1,630
+2% +$6.17K ﹤0.01% 3166
2024
Q1 		$475K Buy
104,847
+2,689
+3% +$13.7K ﹤0.01% 2979
2023
Q4 		$583K Sell
102,158
-95,633
-48% -$443K ﹤0.01% 3028
2023
Q3 		$910K Buy
197,791
+106,970
+118% +$651K ﹤0.01% 2711
2023
Q2 		$587K Buy
90,821
+6,371
+8% +$43.5K ﹤0.01% 3009
2023
Q1 		$637K Buy
84,450
+9,784
+13% +$88.8K ﹤0.01% 2881
2022
Q4 		$757K Buy
74,666
+4,799
+7% +$55.4K ﹤0.01% 2642
2022
Q3 		$691K Buy
69,867
+21,336
+44% +$234K ﹤0.01% 2573
2022
Q2 		$517K Buy
48,531
+7,832
+19% +$66.3K ﹤0.01% 2889
2022
Q1 		$397K Buy
40,699
+13,877
+52% +$131K ﹤0.01% 3437
2021
Q4 		$383K Buy
26,822
+13,738
+105% +$208K ﹤0.01% 3325
2021
Q3 		$262K Buy
13,084
+6,987
+115% +$124K ﹤0.01% 3654
2021
Q2 		$133K Buy
6,097
+1,526
+33% +$42.1K ﹤0.01% 4231
2021
Q1 		$155K Buy
4,571
+3,121
+215% +$124K ﹤0.01% 3976
2020
Q4 		$58K Buy
+1,450
New +$66.3K ﹤0.01% 4454

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Osaic Holdings's ABCL Position: Q1 2026 in Review

Osaic Holdings increased its AbCellera Biologics (ABCL) stake by 0.48% in Q1 2026, buying an estimated $5.96K and bringing the position to 348,978 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2516.

Osaic Holdings first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.44M in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Osaic Holdings held 348,978 shares of AbCellera Biologics worth $1.22M as of Q1 2026.
  • Osaic Holdings bought 1,657 AbCellera Biologics shares in Q1 2026, an estimated $5.96K.
  • AbCellera Biologics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #2516 holding.
  • Osaic Holdings first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Osaic Holdings's AbCellera Biologics position peaked at $1.44M in Q3 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.